Advertisement
Advertisement
U.S. Markets open in 1 hr 27 mins
Advertisement
Advertisement
Advertisement
Advertisement

Orphazyme A/S (ORPHA.CO)

Copenhagen - Copenhagen Real Time Price. Currency in DKK
Add to watchlist
13.39-0.43 (-3.11%)
As of 01:56PM CET. Market open.
Advertisement
Sign in to post a message.
  • K
    Ken
    What does everyone think of this: "the Board of Directors proposes a number of authorizations to be approved by the Extraordinary General Meeting [15 Feb 2022], including authorizations to issue shares, convertible bonds and warrants." Normally, I'd think dilution would be a negative, but if they are betting on approval by the EMA and later the FDA, and thus a pop back to above $6, seems like a positive.
    Bullish
  • s
    stockparty
    Classic, microcap-orphan designation situation, CHiMP --> no one seems to care, company seems to be passed over...kicked around again...sad, really really sad.
    Neutral
  • N
    NP
    Whole market is up today,
    even with some positive movement on EU approval, why does this shows in RED (only one on board)
    Rebound is obvious ........question is when?!!
    Bullish
  • M
    Mehdi
    Go to 20$
  • B
    Baller
    One dollar coming
  • F
    FMTZ
    bought 2k on 7/6/21 @ $6.76 waiting for the European approval
    In Q1 to recover wish me luck
    Bullish
  • F
    Ford
    I'm still optimistic here. If European approval comes through in Q1 I am sure we'll get a nice bump. Then we just keep our fingers crossed for FDA approval at some point in 2022 . The offering was obviously necessary to keep things going. The last biotech that I owned (SAVA) that did a late year offering (everyone was super upset) worked out just fine : )
  • s
    stockparty
    EU approval is a go, what the company does with it is another story. Yes they will make money, but will they or the market decide that they are nevertheless clowned. They need to be stingy to make this work and avoid issuing warrants on any raise because that will set them up to be shorted.
  • s
    stockparty
    "Letter of support for International Niemann-Pick Disease
    Registry (INPDR)" was written october 8th 2021, by Emer Cooke
    Executive Director of the EMA. Current population is 450M approx. France's prevalence is about 1/100,000, for type C so the EU likely has 4500 people with this debilitating disease, but it probably goes un-diagnosed with some regularity. Investors should easily see well over 30 bucks / share. Treatable forms of mental regression really take a huge priority and open the door to broader clinical evaluation say in Alzheimer's Disease etc. I think this stock is going to get treated better than Interferon gamma-1b (ie ACTIMMUNE). They should get a PE of at least 30 over forward earnings. That's going to push this stock towards a market cap of 5B (or more because of the promise ultimately of FDA approval).
    Bullish
  • s
    stockparty
    3.4.3. arimoclomol - Orphan - EMEA/H/C/005203
    Orphazyme A/S; treatment of Niemann-Pick disease type C (NPC)
    Scope: List of experts for an ad-hoc expert group meeting.
    Action: For adoption
    List of Outstanding Issues adopted on 16.09.2021. List of Questions adopted on
    25.03.2021.
  • s
    stockparty
    Amazing how brazen the shorts are, on the eve of victory for ORPH they finally got the stock into the 1 to 2 dollar range.
    Bullish
  • j
    joe
    Thx Gosh I didn’t pay in the 70’s. Lol. In 2’s for sure.
    Bullish
  • K
    Kareem
    I’m in pain, what’s happening here? This has been my worst investment ever… is there hope or I should go ahead and sell?
  • M
    Mr. Market
    Company will not stop selling the $50M at the market offering until stock hits $1.
  • e
    eric
    Pt $1s
  • Y
    Yahoo Finance Insights
    ORPH reached an all time low at 2.47
  • r
    rootbeerfloat
    52 week high $77.77
    so much for thinking 7 is a lucky number
  • N
    NIO
    Just cut another 50% loss. $10K loss just this stock alone. Man, I was up a lot but didn't take profit, thought it might at least hit $10 because the high was $77. The level of manipulation in the market is scary.
  • s
    stockparty
    Short position is low--even they expect this to get approved! The company will have real jamboree. An only approved therapy with a never before approved mechanism f action is going to get this company a lot of attention.
  • J
    Jari
    Game over before X-mas - one board member already left this sinking ship.
    Bearish
Advertisement
Advertisement